HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells

Clinical Immunology

Volumn 106, Issue 1, 2003, Pages 16-22

  Maus, Marcela V ^a   Riley, James L ^a   Kwok, William W ^b   Nepom, Gerald T ^b   June, Carl H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Virginia Mason Research Institute   (United States)

Author keywords

Antigen presenting cells; Costimulation; MHC tetramers

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TETRAMER;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0037288512     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(02)00017-7     Document Type: Article

References (33)

1. Kim J.J., Yang J.S., Nottingham L.K., Tang W., Dang K., Manson K.H., Wyand M.S., Wilson D.M., Weiner D.B. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene. 20:2001;4497-4506.
2. Berns A.J., Clift S., Cohen L.K., Donehower R.C., Dranoff G., Hauda K.M., Jaffee E.M., Lazenby A.J., Levitsky H.I., Marshall F.F. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 6:1995;347-368.
3. Simons J.W., Jaffee E.M., Weber C.E., Levitsky H.I., Nelson W.G., Carducci M.A., Lazenby A.J., Cohen L.K., Finn C.C., Clift S.M., Hauda K.M., Beck L.A., Leiferman K.M., Owens A.H. Jr., Piantadosi S., Dranoff G., Mulligan R.C., Pardoll D.M., Marshall F.F. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57:1997;1537-1546.
4. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., Dahm P., Niedzwiecki D., Gilboa E., Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109:2002;409-417.
5. Jenne L., Schuler G., Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol. 22:2001;102-107.
6. Panelli M.C., Wunderlich J., Jeffries J., Wang E., Mixon A., Rosenberg S.A., Marincola F.M. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp 100. J. Immunother. 23:2000;487-498.
7. Specht J.M., Wang G., Do M.T., Lam J.S., Royal R.E., Reeves M.E., Rosenberg S.A., Hwu P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1997;1213-1221.
8. Dudley M.E., Wunderlich J., Nishimura M.I., Yu D., Yang J.C., Topalian S.L., Schwartzentruber D.J., Hwu P., Marincola F.M., Sherry R., Leitman S.F., Rosenberg S.A. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24:2001;363-373.
9. Rosenberg S.A., Aebersold P., Cornetta K., Kasid A., Morgan R.A., Moen R., Karson E.M., Lotze M.T., Yang J.C., Topalian S.L. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323:1990;570-578.
10. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma Direct evidence of t cell-mediated vitiligo . J. Exp. Med. 192:2000;1637-1644.
11. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., Greenberg P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 257:1992;238-241.
12. Levine B.L., Bernstein W.B., Aronson N.E., Schlienger K., Cotte J., Perfetto S., Humphries M.J., Ratto-Kim S., Birx D.L., Steffens C., Landay A., Carroll R.G., June C.H. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med. 8:2002;47-53.
13. Hurwitz A.A., Yu T.F., Leach D.R., Allison J.P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA. 95:1998;10067-10071.
14. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188:1998;2357-2368.
15. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90:1993;3539-3543.
16. Baxevanis C.N., Voutsas I.F., Tsitsilonis O.E., Gritzapis A.D., Sotiriadou R., Papamichail M. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J. Immunol. 164:2000;3902-3912.
17. Marzo A.L., Kinnear B.F., Lake R.A., Frelinger J.J., Collins E.J., Robinson B.W., Scott B. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165:2000;6047-6055.
18. Lu Z., Yuan L., Zhou X., Sotomayor E., Levitsky H.I., Pardoll D.M. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J. Exp. Med. 191:2000;541-550.
19. Topalian S.L. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr. Opin. Immunol. 6:1994;741-745.
20. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., Wu T.C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:1996;21-26.
21. Pardoll D.M., Topalian S.L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:1998;588-594.
22. Wang R.F. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 22:2001;269-276.
23. Topalian S.L., Rivoltini L., Mancini M., Ng J., Hartzman R.J., Rosenberg S.A. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer. 58:1994;69-79.
24. Housseau F., Langer D.A., Oberholtzer S.D., Moorthy A., Levitsky H.I., Pardoll D.M., Topalian S.L. Tumor-specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines. Int. J. Cancer. 98:2002;57-62.
25. Bergwelt-Baildon M.S., Vonderheide R.H., Maecker B., Hirano N., Anderson K.S., Butler M.O., Xia Z., Zeng W.Y., Wucherpfennig K.W., Nadler L.M., Schultze J.L. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells Potential for clinical application . Blood. 99:2002;3319-3325.
26. Brodie S.J., Lewinsohn D.A., Patterson B.K., Jiyamapa D., Krieger J., Corey L., Greenberg P.D., Riddell S.R. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5:1999;34-41.
27. Schlienger K., Craighead N., Lee K.P., Levine B.L., June C.H. Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. Blood. 96:2000;3490-3498.
28. Stevens E.J., Jacknin L., Robbins P.F., Kawakami Y., El Gamil M., Rosenberg S.A., Yannelli J.R. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. J. Immunol. 154:1995;762-771.
29. Levine B.L., Bernstein W.B., Connors M., Craighead N., Lindsten T., Thompson C.B., June C.H. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159:1997;5921-5930.
30. A.K. Thomas, M.V. Maus, W.S. Shalaby, C.H. June, J.L. Riley, A cell based artificial antigen presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long term growth of CD4 T lymphocytes, Clin. Immunol., in press (2002).
31. Maus M.V., Thomas A.K., Leonard D.G., Allman D., Addya K., Schlienger K., Riley J.L., June C.H. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 20:2002;143-148.
32. Novak E.J., Liu A.W., Nepom G.T., Kwok W.W. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J. Clin. Invest. 104:1999;R63-R67.
33. June C.H., Ledbetter J.A., Gillespie M.M., Lindsten T., Thompson C.B. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell Biol. 7:1987;4472-4481.